MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.aed.2026.04.001

Медицинская библиотека · AACE endocrinology and diabetes · 2026

Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema.

Levy Barnett Maxim John, Siqueira Tavares de Melo Maria Helena, de Medeiros Rego Maria Luiza

СтатьяОбзорПеревод в очереди

Аннотация

BACKGROUND

Pretibial myxedema is an infrequent dermatologic manifestation of autoimmune thyroid disease characterized by glycosaminoglycan deposition within the dermis. Treatment options are limited, lacking durable effect and remain largely palliative. Emerging evidence, however, suggests pretibial myxedema may share a common pathophysiology with thyroid eye disease, raising the possibility that inhibition of the insulin-like growth factor-1 receptor may offer therapeutic benefit.

METHODS

With the scant literature documenting a response (or lack thereof) to teprotumumab therapy for pretibial myxedema, our objective is to thematically analyze and review the existing literature pertaining to this lesser-known phenomenon, with particular emphasis on clinical response and durability. A scoping review was performed with a search of 3 databases between January 2020 and 2026. Eligible studies included patients with pretibial myxedema with exposure to teprotumumab. Data extraction included study characteristics, patient demographics, treatment regimens, time to clinical improvement, relapse patterns, and follow-up duration.

RESULTS

Overall, n = 14 studies met inclusion criteria (n = 31 patients). All studies consistently noted an improvement with clinical responses noted early, often within the first to fourth infusions. Relapses occurred in a subset of patients, often months after completing treatment; however, repeat exposure continued to demonstrate persistent benefits in many reported studies.

CONCLUSIONS

Teprotumumab demonstrated improvement in pretibial myxedema, supporting the notion of a shared pathophysiologic basis with thyroid eye disease. Prospective registries and standardized outcome measures are needed to define durability, retreatment strategies, and long-term safety.

Для цитирования: Levy Barnett Maxim John, Siqueira Tavares de Melo Maria Helena, de Medeiros Rego Maria Luiza. Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema.. AACE endocrinology and diabetes. 2026. DOI: 10.1016/j.aed.2026.04.001.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.